272 related articles for article (PubMed ID: 29642234)
1. A retrospective investigation of HLA-B*5801 in hyperuricemia patients in a Han population of China.
Cheng H; Yan D; Zuo X; Liu J; Liu W; Zhang Y
Pharmacogenet Genomics; 2018 May; 28(5):117-124. PubMed ID: 29642234
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study.
Yu KH; Lai JH; Hsu PN; Chen DY; Chen CJ; Lin HY
Scand J Rheumatol; 2016 Jul; 45(4):304-11. PubMed ID: 26771445
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore.
Pruis SL; Jeon YK; Pearce F; Thong BY; Aziz MIA
J Med Econ; 2020 Aug; 23(8):838-847. PubMed ID: 32301360
[No Abstract] [Full Text] [Related]
4. Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy.
Ruggeri M; Basile M; Drago C; Rolli FR; Cicchetti A
Pharmacoeconomics; 2018 May; 36(5):625-636. PubMed ID: 29557073
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of febuxostat in patients with gout in Spain.
Perez-Ruiz F; Díaz-Torné C; Carcedo D
J Med Econ; 2016 Jun; 19(6):604-10. PubMed ID: 26855041
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore.
Dong D; Tan-Koi WC; Teng GG; Finkelstein E; Sung C
Pharmacogenomics; 2015 Nov; 16(16):1781-93. PubMed ID: 26554739
[TBL] [Abstract][Full Text] [Related]
7. Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: a cost-effectiveness analysis for Spanish patients.
Presa M; Pérez-Ruiz F; Oyagüez I
Clin Rheumatol; 2019 Dec; 38(12):3521-3528. PubMed ID: 31420811
[TBL] [Abstract][Full Text] [Related]
8. Is HLA-B*58:01 genotyping cost effective in guiding allopurinol use in gout patients with chronic kidney disease?
Teng GG; Tan-Koi WC; Dong D; Sung C
Pharmacogenomics; 2020 Mar; 21(4):279-291. PubMed ID: 32180492
[No Abstract] [Full Text] [Related]
9. Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease.
Mitri G; Wittbrodt ET; Turpin RS; Tidwell BA; Schulman KL
J Manag Care Spec Pharm; 2016 Apr; 22(4):326-36. PubMed ID: 27023686
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions.
Ke CH; Chung WH; Wen YH; Huang YB; Chuang HY; Tain YL; Wang YL; Wu CC; Hsu CN
J Rheumatol; 2017 Jun; 44(6):835-843. PubMed ID: 28365572
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia.
Wang S
Pak J Pharm Sci; 2018 Jul; 31(4(Special)):1623-1627. PubMed ID: 30203749
[TBL] [Abstract][Full Text] [Related]
12. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
[TBL] [Abstract][Full Text] [Related]
13. Febuxostat in the management of gout: a cost-effectiveness analysis.
Smolen LJ; Gahn JC; Mitri G; Shiozawa A
J Med Econ; 2016; 19(3):265-76. PubMed ID: 26535593
[TBL] [Abstract][Full Text] [Related]
14. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.
Tassaneeyakul W; Jantararoungtong T; Chen P; Lin PY; Tiamkao S; Khunarkornsiri U; Chucherd P; Konyoung P; Vannaprasaht S; Choonhakarn C; Pisuttimarn P; Sangviroon A; Tassaneeyakul W
Pharmacogenet Genomics; 2009 Sep; 19(9):704-9. PubMed ID: 19696695
[TBL] [Abstract][Full Text] [Related]
15. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
Cutolo M; Cimmino MA; Perez-Ruiz F
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
[TBL] [Abstract][Full Text] [Related]
16. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
[TBL] [Abstract][Full Text] [Related]
17. A lifetime economic research of universal HLA-B*58:01 genotyping or febuxostat initiation therapy in Chinese gout patients with mild to moderate chronic kidney disease.
Hong Y; Chen X; Li Z; Zhang X; Zhou C; Wang Y; Wang G; Wu W; Zhou D; Feng Li H
Pharmacogenet Genomics; 2023 Feb; 33(2):24-34. PubMed ID: 36729770
[TBL] [Abstract][Full Text] [Related]
18. HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.
Yeo SI
Int J Rheum Dis; 2013 Jun; 16(3):254-7. PubMed ID: 23981744
[TBL] [Abstract][Full Text] [Related]
19. Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.
Stevenson M; Pandor A
Health Technol Assess; 2009 Oct; 13 Suppl 3():37-42. PubMed ID: 19846027
[TBL] [Abstract][Full Text] [Related]
20. Febuxostat for the chronic management of hyperuricemia in patients with gout.
Chinchilla SP; Urionaguena I; Perez-Ruiz F
Expert Rev Clin Pharmacol; 2016; 9(5):665-73. PubMed ID: 26942273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
